Breaking News
June 19, 2018 - JAK inhibitors associated with aggressive lymphoma
June 19, 2018 - SetPoint announces positive long-term results of bioelectronic medicine to treat rheumatoid arthritis
June 19, 2018 - Hypnosis may help reduce fear, anxiety in children undergoing treatment for cancer
June 19, 2018 - Scientists point to potentially promising treatment target for deadly brain cancers
June 19, 2018 - After opioid overdose, only 30 percent get medicine to treat addiction
June 19, 2018 - Patients with mild Alzheimer’s disease over age 65 continue to derive benefit from DBS-f treatment
June 19, 2018 - Microbiotica partners with University of Adelaide to develop defined bacterial product for ulcerative colitis
June 19, 2018 - Paratek Presents New Analysis from Combined Phase 3 Skin Infection Studies Highlighting Efficacy of Omadacycline in Treating Drug Resistant S. aureus
June 19, 2018 - Autism is not linked to eating fish in pregnacy
June 19, 2018 - Scientists create universal assembly method to enhance cancer therapy and diagnostics
June 19, 2018 - FDA provides guidance on Novus Therapeutics’ development path for OP-02 to treat otitis media
June 19, 2018 - Award granted to Neem Biotech to develop antimicrobial intervention for chronic lung infections
June 19, 2018 - Study finds combined risk of death and developing cancer to be lowest in light drinkers
June 19, 2018 - Novel app teaches users how to stop life-threatening bleeding and save lives
June 19, 2018 - Single blood sample can provide adequate confirmation of diabetes
June 19, 2018 - New stimulation method increases hope for improving disorders of consciousness
June 19, 2018 - FDA Issues Complete Response Letter for Duobrii (halobetasol propionate and tazarotene) Lotion
June 19, 2018 - Defining the biology of autism
June 19, 2018 - Researchers use optogenetics to shape tissues
June 19, 2018 - Scientists discover genetic causes underlying group of related infant cancers
June 19, 2018 - Innovative digital home testing kit benefits patients with kidney conditions
June 19, 2018 - New guidance on selection and evaluation of wearable devices for use in regulatory clinical trials
June 19, 2018 - Researchers understand the role of brain’s ‘reward circuit’ in autism spectrum disorder
June 19, 2018 - Researchers propose new strategy to combat micro-pollutants in water
June 19, 2018 - Illicit Opioid Trade Up With Restrictions on Hydrocodone
June 19, 2018 - New 3-D imaging analysis technique could lead to improved arthritis treatment
June 19, 2018 - Study finds increased risk of mortality in people with cold agglutinin disease in five years after diagnosis
June 19, 2018 - Psychologists can play important role in treating alcohol problems
June 19, 2018 - Study finds elevated risk of congenital defects in lithium-exposed infants
June 19, 2018 - Test-Taking Can Be Tough for Kids With Vision Problems
June 19, 2018 - Injections for knee osteoarthritis—’subtle but significant’ impact of revisions in clinical practice guidelines
June 19, 2018 - Researchers develop new approach to assess effectiveness of Men B vaccine
June 19, 2018 - Study shows link between financial literacy and hospitalization risk in older adults
June 19, 2018 - If you’ve got hep C, spitting can be a felony
June 19, 2018 - New study examines how the brain plays role in rheumatoid arthritis inflammation
June 19, 2018 - Researchers discover new defense mechanism against oxygen radicals
June 19, 2018 - WVU researcher aims to produce updated whooping cough vaccine
June 19, 2018 - Scientists develop novel computational framework to support personalized cancer treatment
June 19, 2018 - Rate of dementia on the decline—but beware of growing numbers
June 19, 2018 - Microglia play protective role in response to retinal detachment, shows study
June 19, 2018 - Technology breakthrough could enable detection of fetal genetic abnormalities in early pregnancy
June 19, 2018 - Novel chip can be used to identify rhinovirus strains as cause of asthma
June 19, 2018 - Effects of in vitro fertilization depend on genetic variation inherited from parents
June 19, 2018 - Heart attack patients unable to resume work report depression and financial hardship
June 19, 2018 - Study combines gene editing and stem cell technologies to predict person’s risk for heart disease
June 19, 2018 - Weight loss of 20% or greater results in better outcomes for overweight, obese adults with knee osteoarthritis
June 19, 2018 - Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
June 19, 2018 - Study predicts most people with earliest Alzheimer’s signs won’t develop dementia associated with the disease
June 19, 2018 - Abnormal sleep duration linked to metabolic syndrome in new study
June 19, 2018 - Researchers develop new method to preserve fertility in boys with prepubertal cancer
June 19, 2018 - Late onset of diabetes could be indicative of pancreatic cancer
June 19, 2018 - WHO releases new International Classification of Diseases (ICD-11)
June 19, 2018 - Skin tone makes big difference in diagnosis and treatment of dermatologic conditions
June 19, 2018 - After addiction, the long road back to good health
June 19, 2018 - High blood pressure could be an early sign of dementia
June 19, 2018 - Innovative drugs and new European treatment guidelines refine, improve MS therapy
June 19, 2018 - BIDMC scientists develop new tool to benefit patients with HCV-associated liver failure
June 19, 2018 - Diabetes diagnosis may come with increased risk of pancreatic cancer for African-Americans, Latinos
June 19, 2018 - Personalized Goals, Cash Motivate Heart Patients to Exercise
June 19, 2018 - Nipah Virus (NiV) | CDC
June 19, 2018 - Genomics offers new treatment options for infants with range of soft tissue tumors
June 18, 2018 - Study shows how moderate consumption of alcohol can protect the heart
June 18, 2018 - Gene editing technology predicts heart disease risk
June 18, 2018 - Who Will and Who Won’t Get the Flu?
June 18, 2018 - Research shows effective responses to online feedback
June 18, 2018 - Scientists to focus on big data and genetics to identify risk factors for dementia
June 18, 2018 - Ultrasound-based technology for assessing overweight adolescents with liver disease
June 18, 2018 - Osteochondral knee defect treated using cell technology
June 18, 2018 - New clinical trial finds no evidence to support use of tamsulosin for kidney stones
June 18, 2018 - Study demonstrates increased levels of gum disease in people at risk of rheumatoid arthritis
June 18, 2018 - Ebola & Marburg | NIH: National Institute of Allergy and Infectious Diseases
June 18, 2018 - Brains, eyes, testes: off-limits for transplants?
June 18, 2018 - Drug used to treat myelofibrosis can awaken ‘dormant’ lymphomas in the bone marrow
June 18, 2018 - New study focuses on best, cost effective practices to bridge treatment gap for brain disorders
June 18, 2018 - New study highlights predictors that prevent from achieving remission in early RA
June 18, 2018 - Neuroscientists map feeling of cool touch to the brain’s insula in mouse model
June 18, 2018 - Study highlights potential use of blood biomarkers as diagnostic tool for sleep apnea
June 18, 2018 - Eating plant-based diet can reduce risk for heart problems in people with type 2 diabetes
June 18, 2018 - Lenabasum has acceptable safety and tolerability in diffuse cutaneous systemic sclerosis
June 18, 2018 - Study shows link between risky opioid prescriptions and increased odds of death
Enzalutamide Safe In Seizure-Prone Prostate CA Patients

Enzalutamide Safe In Seizure-Prone Prostate CA Patients

image_pdfDownload PDFimage_print

Action Points

  • The androgen receptor inhibitor enzalutamide (Xtandi) did not raise seizure incidence when used at a dose of 160 mg/day in men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, in a multicenter, multinational trial.
  • Note that the data, along with the previously established efficacy profile, suggest that enzalutamide does not predispose to seizures and may be safely used in men with metastatic prostate cancer who have risk factors for seizure.

In men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, the androgen receptor inhibitor enzalutamide (Xtandi) didn’t raise seizure incidence when used at a dose of 160 mg/day, researchers found in a manufacturer-sponsored study.

Confirmed seizure incidence in the Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide (UPWARD) was 2.6 per 100 patient-years, according to Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues.

That’s about the same as the incidence previously calculated in a large retrospective analysis in the U.S., at 2.8 per 100 patient-years in patients with mCRPC and seizure risk factors who never took the drug, Slovin and colleagues reported online in JAMA Oncology.

“These data suggest that enzalutamide did not increase seizure incidence in men with mCRPC and seizure risk factors and is an option for patients with seizure risk factors,” the researchers wrote. “However, it should be used with caution and input from neurology specialists.”

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they added.

Jim Hu, MD, MPH, of New York Presbyterian/Weill Cornell Medicine in New York City, who wasn’t involved in the study, noted that the results contrast to those of a prior study, but they do suggest that “enzalutamide does not predispose to seizure. This demonstrates that enzalutamide may be safely used in men with metastatic prostate cancer who have risk factors for seizure.”

UPWARD was initiated following requests for additional safety information from the FDA and the European Medicines Agency. Although enzalutamide is known to prolong survival in men with mCRPC, phase I and II studies reported seizures in 3 of 140 (2%) enzalutamide-treated patients at doses greater than 360 mg/day.

Controlled clinical trials such as AFFIRM, PREVAIL, TERRAIN, and STRIVE have shown that with 160 mg of oral enzalutamide daily, only 0.5% of patients experienced seizure. However, patients with a history of seizure or risk factors were excluded from these trials, the researchers noted.

For UPWARD, they evaluated 423 patients at 73 sites in 20 countries, all of whom had at least one risk factor for seizure, including medications that lowered seizure threshold (57.2%); history of brain injury (26.5%); and history of cerebrovascular accident or transient ischemic attack (22.2%).

All patients received oral enzalutamide at a dose of 160 mg/day for an initial 4-month treatment period, and were given the option to extend treatment for one year.

Overall, 4 out of 366 evaluable patients (1.1%) had at least one confirmed seizure within 4 months of starting enzalutamide. The seizures were considered enzalutamide-related in 3 of the 4 patients. In addition, 3 patients (0.8%) had a seizure in the 4-month period after the study ended.

All 423 patients were included in the safety analysis. The majority (84.4%) experienced at least one treatment-emergent adverse event: 33.3% had at least one serious treatment-emergent adverse event, and 6.9% had at least one drug-related serious adverse event.

A total of 66 patients (15.6%) permanently discontinued treatment as a result of a drug-related AE, and three of these patients had a seizure, the researchers reported.

During the 4-month study period or within 30 days of the treatment ending, there were 38 deaths (9%), four of which were considered possibly drug-related. One patient died of cerebral hemorrhage, one of mCRPC progression, one experienced sudden cardiac death, and another had general deterioration. No seizure-related deaths were reported.

Study limitations included the fact that a randomized controlled trial wasn’t feasible, and that predisposing risk factors for seizure such as a history of seizure or of brain arteriovenous malformations were underrepresented, the researchers said.

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they concluded.

This study was funded by Astellas Pharma and Medivation (acquired by Pfizer in September 2016), the co-developers of enzalutamide. Both sponsors participated in the design and conduct of the study as well as analysis and interpretation of the data, approval of the manuscript, and decision to submit for publication. Lead author Slovin reported a relationship with Bayer AG. A number of co-authors also reported relationships with industry, including Astellas Pharma, Medivation, and Pfizer.


Tagged with:

About author

Related Articles